Treatment with an experimental drug delivered through a minimally invasive procedure may show promise in patients with liver cancer that cannot be treated with surgery.
A small group of patients with early- or intermediate-stage hepatocellular carcinoma, the most common type of primary liver cancer, that cannot be surgically resected, derived a benefit from treatment with an experimental drug, according to findings from an early-phase trial.
“The current standard of care for unresectable liver cancer is conventional transarterial chemoembolization (TACE) with the chemotherapeutic agent doxorubicin,” Dr. Chang-Hsien Liu, the primary investigator of the study, said in a press release announcing the findings. “Though well established, TACE with doxorubicin has limited efficacy because chemotherapy does not effectively kill cancer stem cells, a root cause for tumor recurrence after TACE. Additionally, embolization-induced tumor hypoxia (low levels of oxygen) is thought to dampen the cytotoxic (cell-damaging) effects of doxorubicin.”
According to the National Cancer Institute, a transarterial chemoembolization is a minimally invasive procedure in which the blood supply to a tumor or an abnormal area of tissue is blocked. Members of the patient’s health care team make a small call in the inner thigh. Then, a thin, flexible tube is inserted into the incision and guided into an artery near the tumor or abnormal tissue and the treatment is subsequently delivered.
In this phase 1 study, 17 patients with early- or intermediate-stage hepatocellular carcinoma were all given treatment with an experimental anti-cancer drug known as tirapazamine delivered via transarterial chemoembolization. Patients enrolled onto the trial were allowed to have received previous treatment.
The findings — which were published in The Journal of Vascular and Interventional Radiology — showed that treatment with the experimental anti-cancer drug tirapazamine resulted in a complete response (meaning that the cancer completely responded to treatment) in eight of the 17 patients, or 47.1% of the study population.
Additionally, three patients achieved a partial response. The early findings also showed that this treatment was associated with a six-month progression-free survival (percentage of patients alive without disease progression) rate of 72.6% and a median overall survival (length of time a patient is alive without death from any cause) of 29.3 months.
In the press release, Liu noted that these results show that the experimental anti-cancer drug tirapazamine could be a viable alternative to the chemotherapy doxorubicin.
“The results of this study support tirapazamine as an alternative to doxorubicin in trans-arterial chemoembolization,” he said. “A future randomized study is warranted to compare tirapazamine and doxorubicin under embolization.”
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.